INTRODUCTION: Proinflammatory cytokines play an important role in the development of type 1 diabetes. Lisofylline (LSF) is a novel anti-inflammatory compound that specifically inhibits proinflammatory cytokine production and action. AIM: To investigate the effect of LSF on diabetes prevention. METHODOLOGY: A mouse with diabetes induced by multiple low doses of streptozotocin (STZ) can be used as an animal model for type 1 diabetes. In this study, we used this method to induce diabetes in C57BL/6J mice. The daily LSF treatment started 5 days before STZ injections and lasted for 2 weeks. The incidence of diabetes was monitored. Insulin secretion was assessed in pancreatic islets isolated from experimental mice. Cytokine production was measured in mouse sera. Islet apoptosis was assessed quantitatively. RESULTS: In LSF-treated mice, there was a significant reduction of diabetes incidence (25% vs. 91.6%). This protection was associated with suppression of systemic levels of IFN-gamma and TNF-alpha, inhibition of macrophage infiltration in islets, restoration of islet insulin secretion, and reduction of beta-cell apoptosis. CONCLUSIONS: This study suggests that treatment with LSF suppresses proinflammatory cytokines and protects beta-cells from inflammation. LSF may be useful for prevention of type 1 diabetes and other disorders associated with excessive proinflammatory cytokines.
INTRODUCTION: Proinflammatory cytokines play an important role in the development of type 1 diabetes. Lisofylline (LSF) is a novel anti-inflammatory compound that specifically inhibits proinflammatory cytokine production and action. AIM: To investigate the effect of LSF on diabetes prevention. METHODOLOGY: A mouse with diabetes induced by multiple low doses of streptozotocin (STZ) can be used as an animal model for type 1 diabetes. In this study, we used this method to induce diabetes in C57BL/6J mice. The daily LSF treatment started 5 days before STZ injections and lasted for 2 weeks. The incidence of diabetes was monitored. Insulin secretion was assessed in pancreatic islets isolated from experimental mice. Cytokine production was measured in mouse sera. Islet apoptosis was assessed quantitatively. RESULTS: In LSF-treated mice, there was a significant reduction of diabetes incidence (25% vs. 91.6%). This protection was associated with suppression of systemic levels of IFN-gamma and TNF-alpha, inhibition of macrophage infiltration in islets, restoration of islet insulin secretion, and reduction of beta-cell apoptosis. CONCLUSIONS: This study suggests that treatment with LSF suppresses proinflammatory cytokines and protects beta-cells from inflammation. LSF may be useful for prevention of type 1 diabetes and other disorders associated with excessive proinflammatory cytokines.
Authors: Y Imai; A D Dobrian; J R Weaver; M J Butcher; B K Cole; E V Galkina; M A Morris; D A Taylor-Fishwick; J L Nadler Journal: Diabetes Obes Metab Date: 2013-09 Impact factor: 6.577
Authors: Daniela S Masson-Meyers; Thiago A M Andrade; Guilherme F Caetano; Francielle R Guimaraes; Marcel N Leite; Saulo N Leite; Marco Andrey C Frade Journal: Int J Exp Pathol Date: 2020-03-30 Impact factor: 1.925
Authors: D A Taylor-Fishwick; J R Weaver; W Grzesik; S Chakrabarti; S Green-Mitchell; Y Imai; N Kuhn; J L Nadler Journal: Diabetologia Date: 2012-10-03 Impact factor: 10.122
Authors: E Scott Colvin; Hong-Yun Ma; Yi-Chun Chen; Angelina M Hernandez; Patrick T Fueger Journal: Endocrinology Date: 2013-02-05 Impact factor: 4.736
Authors: Elodie Masson; Shlomit Koren; Fathima Razik; Howard Goldberg; Edwin P Kwan; Laura Sheu; Herbert Y Gaisano; I George Fantus Journal: Am J Physiol Endocrinol Metab Date: 2009-02-17 Impact factor: 4.310